Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Group 1 - Replimune Group, Inc. announced that a late-breaking abstract featuring the IGNYTE clinical trial primary analysis has been selected for oral presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) [1] - The ARTACUS clinical trial data of RP1 monotherapy in solid organ transplant patients with advanced cutaneous malignancies will be shared in an encore poster presentation [1] - The IGNYTE trial focuses on patients with anti-PD1 failed melanoma, presenting clinical subgroup and initial biomarker data [2] Group 2 - Replimune was founded in 2015 and aims to transform cancer treatment through novel oncolytic immunotherapies [3] - The proprietary RPx platform utilizes a potent HSV-1 backbone to maximize immunogenic cell death and induce a systemic anti-tumor immune response [3] - RPx product candidates are designed for dual local and systemic activity, allowing for synergy with established and experimental cancer treatment modalities [3]